Here, we exploited the filamentous bacteriophage antigen delivery system, improved by the co-delivery of the immunomodulating lipid α-GalCer, to stimulate innate and adaptive responses against the human tumor antigen NY-ESO-1. The gene discussed is CTAG1B; the disease is neoplasm.